Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 3/10

vs
industry
vs
history
Cash to Debt 2.17
CHRS's Cash to Debt is ranked lower than
71% of the 959 Companies
in the Global Biotechnology industry.

( Industry Median: 50.45 vs. CHRS: 2.17 )
Ranked among companies with meaningful Cash to Debt only.
CHRS' s Cash to Debt Range Over the Past 10 Years
Min: 1.75  Med: No Debt Max: No Debt
Current: 2.17
Equity to Asset -0.24
CHRS's Equity to Asset is ranked lower than
94% of the 702 Companies
in the Global Biotechnology industry.

( Industry Median: 0.68 vs. CHRS: -0.24 )
Ranked among companies with meaningful Equity to Asset only.
CHRS' s Equity to Asset Range Over the Past 10 Years
Min: -2.05  Med: 0.06 Max: 0.39
Current: -0.24
-2.05
0.39
F-Score: 2
Z-Score: -3.12
M-Score: -5.41
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 3/10

vs
industry
vs
history
Operating margin (%) -572.05
CHRS's Operating margin (%) is ranked lower than
71% of the 748 Companies
in the Global Biotechnology industry.

( Industry Median: -85.53 vs. CHRS: -572.05 )
Ranked among companies with meaningful Operating margin (%) only.
CHRS' s Operating margin (%) Range Over the Past 10 Years
Min: -2028.33  Med: -1018.8 Max: -207.94
Current: -572.05
-2028.33
-207.94
Net-margin (%) -591.61
CHRS's Net-margin (%) is ranked lower than
73% of the 748 Companies
in the Global Biotechnology industry.

( Industry Median: -80.71 vs. CHRS: -591.61 )
Ranked among companies with meaningful Net-margin (%) only.
CHRS' s Net-margin (%) Range Over the Past 10 Years
Min: -1949.65  Med: -1240.94 Max: -280.12
Current: -591.61
-1949.65
-280.12
ROE (%) -30747.69
CHRS's ROE (%) is ranked lower than
100% of the 871 Companies
in the Global Biotechnology industry.

( Industry Median: -32.29 vs. CHRS: -30747.69 )
Ranked among companies with meaningful ROE (%) only.
CHRS' s ROE (%) Range Over the Past 10 Years
Min: -30747.69  Med: -736.9 Max: -736.9
Current: -30747.69
-30747.69
-736.9
ROA (%) -113.47
CHRS's ROA (%) is ranked lower than
89% of the 962 Companies
in the Global Biotechnology industry.

( Industry Median: -27.73 vs. CHRS: -113.47 )
Ranked among companies with meaningful ROA (%) only.
CHRS' s ROA (%) Range Over the Past 10 Years
Min: -145  Med: -118.09 Max: -74.26
Current: -113.47
-145
-74.26
ROC (Joel Greenblatt) (%) -2806.85
CHRS's ROC (Joel Greenblatt) (%) is ranked lower than
74% of the 922 Companies
in the Global Biotechnology industry.

( Industry Median: -382.66 vs. CHRS: -2806.85 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
CHRS' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: -2990.18  Med: -2783.84 Max: -1962.87
Current: -2806.85
-2990.18
-1962.87
» CHRS's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow
Oprt. Cash Flow & Net Income

» Details

Guru Trades

Q3 2015

CHRS Guru Trades in Q3 2015

Jim Simons 85,500 sh (+109.01%)
George Soros 127,600 sh (unchged)
» More
Q4 2015

CHRS Guru Trades in Q4 2015

George Soros 127,600 sh (unchged)
Jim Simons Sold Out
» More
Q1 2016

CHRS Guru Trades in Q1 2016

Steven Cohen 131,200 sh (New)
George Soros Sold Out
» More
Q2 2016

CHRS Guru Trades in Q2 2016

Paul Tudor Jones 11,300 sh (New)
Jim Simons 94,500 sh (New)
Steven Cohen 37,500 sh (-71.42%)
» More
» Details

Insider Trades

Latest Guru Trades with CHRS

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology
Compare:NAS:CEMP, NAS:PTLA, OTCPK:PFSCF, NAS:ACOR, OTCPK:SXMDF, NAS:INVA, NAS:FGEN, OTCPK:AKBLF, NAS:DERM, OTCPK:BVNRY, NAS:ACHN, NAS:CLVS, NAS:RLYP, NYSE:EBS, NAS:XLRN, NAS:SAGE, NYSE:CBM, NAS:AAAP, NYSE:AXON, NAS:MGNX » details
Coherus BioSciences Inc is a late-stage clinical biologics platform company. The Company is engaged in developing biosimilar therapeutics.

Ratios

vs
industry
vs
history
P/S 26.69
CHRS's P/S is ranked lower than
68% of the 685 Companies
in the Global Biotechnology industry.

( Industry Median: 12.19 vs. CHRS: 26.69 )
Ranked among companies with meaningful P/S only.
CHRS' s P/S Range Over the Past 10 Years
Min: 6.8  Med: 17.89 Max: 35.73
Current: 26.69
6.8
35.73
Current Ratio 2.19
CHRS's Current Ratio is ranked lower than
73% of the 932 Companies
in the Global Biotechnology industry.

( Industry Median: 4.35 vs. CHRS: 2.19 )
Ranked among companies with meaningful Current Ratio only.
CHRS' s Current Ratio Range Over the Past 10 Years
Min: 0.85  Med: 2.38 Max: 3.46
Current: 2.19
0.85
3.46
Quick Ratio 2.19
CHRS's Quick Ratio is ranked lower than
68% of the 932 Companies
in the Global Biotechnology industry.

( Industry Median: 4.15 vs. CHRS: 2.19 )
Ranked among companies with meaningful Quick Ratio only.
CHRS' s Quick Ratio Range Over the Past 10 Years
Min: 0.85  Med: 2.38 Max: 3.46
Current: 2.19
0.85
3.46
Days Sales Outstanding 3.49
CHRS's Days Sales Outstanding is ranked higher than
94% of the 588 Companies
in the Global Biotechnology industry.

( Industry Median: 62.24 vs. CHRS: 3.49 )
Ranked among companies with meaningful Days Sales Outstanding only.
CHRS' s Days Sales Outstanding Range Over the Past 10 Years
Min: 3.49  Med: 29.37 Max: 36.88
Current: 3.49
3.49
36.88

Buy Back

vs
industry
vs
history

Valuation & Return

vs
industry
vs
history
Price/Median PS Value 1.49
CHRS's Price/Median PS Value is ranked lower than
73% of the 616 Companies
in the Global Biotechnology industry.

( Industry Median: 1.01 vs. CHRS: 1.49 )
Ranked among companies with meaningful Price/Median PS Value only.
CHRS' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.49  Med: 0.95 Max: 1.57
Current: 1.49
0.49
1.57
Earnings Yield (Greenblatt) (%) -21.70
CHRS's Earnings Yield (Greenblatt) (%) is ranked lower than
73% of the 928 Companies
in the Global Biotechnology industry.

( Industry Median: -8.60 vs. CHRS: -21.70 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
CHRS' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: -64.62  Med: 0 Max: 0
Current: -21.7
-64.62
0

More Statistics

Revenue (TTM) (Mil) $43.79
EPS (TTM) $ -6.58
Short Percentage of Float17.55%
52-Week Range $12.04 - 31.98
Shares Outstanding (Mil)43.38
» More Articles for CHRS

Headlines

Articles On GuruFocus.com
A Look at Pharma Company Dermira's Performance Mar 27 2015 

More From Other Websites
ETF’s with exposure to Coherus BioSciences, Inc. : September 19, 2016 Sep 19 2016
Coherus BioSciences Announces New Employment Inducement Grants Sep 16 2016
Coherus BioSciences Announces New Employment Inducement Grants Sep 16 2016
AbbVie's Battle Royale Sep 14 2016
Coverage initiated on Coherus BioSciences by Maxim Group Sep 07 2016
2 Biotech Biosimilar Winners Sep 01 2016
Coherus BioSciences Management to Present at Two Investor Healthcare Conferences in September Sep 01 2016
Coherus BioSciences Management to Present at Two Investor Healthcare Conferences in September Sep 01 2016
Coherus BioSciences Announces New Employment Inducement Grants Aug 31 2016
Coherus BioSciences Announces New Employment Inducement Grants Aug 31 2016
ETF’s with exposure to Coherus BioSciences, Inc. : August 29, 2016 Aug 29 2016
COHERUS BIOSCIENCES, INC. Financials Aug 18 2016
Coherus Biosciences Inc (CHRS) Has Set Its Sights On Amgen, Inc. (AMGN) Aug 16 2016
ETF’s with exposure to Coherus BioSciences, Inc. : August 15, 2016 Aug 15 2016
Coherus BioSciences, Inc. :CHRS-US: Earnings Analysis: Q2, 2016 By the Numbers : August 12, 2016 Aug 12 2016
Yelp Inc (YELP) Swung To Surprising Profit; A Look at Four Other Earnings Reports Aug 10 2016
Coherus BioSciences reports 2Q loss Aug 09 2016
Coherus BioSciences reports 2Q loss Aug 09 2016
Coherus BioSciences Inc Earnings Call scheduled for 4:30 pm ET today Aug 09 2016
Coherus BioSciences Reports Second Quarter 2016 Financial and Operating Results Aug 09 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)